News Related to Fractional Exhaled Nitric Oxide

Related coverage linked through entity extraction aliases.

Aclaris Therapeutics Details TSLP/ITK Pipeline with Multiple Clinical Readouts Expected in Late 2026

Apr 28, 2026

Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.

Upstream Bio Reports Positive Phase 2 Data for Verekitug in Nasal Polyps and Severe Asthma

Mar 01, 2026

Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.